Immunomodulation Effect of Convalescent Plasma Therapy in Severe – Critical COVID-19 Patients

References

• Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671–1692. doi:10.1016/j.cell.2021.02.029
   PubMed Web of Science ®Google Scholar
• Dhar SK, Gujar S, Gujar S, Das M, Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 2021;7(2):e06155. doi:10.1016/j.heliyon.2021.e06155
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: a brief look at potential therapeutic tactics. Life Sci. 2020;257:118097. doi:10.1016/j.lfs.2020.118097
   PubMed Web of Science ®Google Scholar
• Schuerwegh AJ, Dombrecht EJ, Stevens WJ, Van Offel JF, Bridts CH, De Clerck LS. Influence of pro-inflammatory (IL-1 alpha, IL-6, TNF-alpha, IFN-gamma) and anti-inflammatory (IL-4) cytokines on chondrocyte function. Osteoarthritis Cartilage. 2003;11(9):681–687. doi:10.1016/s1063-4584(03)00156-0
   PubMed Web of Science ®Google Scholar
• Vaz de Paula CB, de Azevedo MLV, Nagashima S, et al. IL-4/IL-13 remodeling pathway of COVID-19 lung injury. Sci Rep. 2020;10(1):18689. doi:10.1038/s41598-020-75659-5
   PubMed Web of Science ®Google Scholar
• Merza MY, Hwaiz RA, Hamad BK, Mohammad KA, Hama HA, Karim AY. Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan Region of Iraq. PLoS One. 2021;16(4):e0250330. doi:10.1371/journal.pone.0250330
   PubMed Web of Science ®Google Scholar
• Rojas M, Monsalve DM, Pacheco Y, et al. Ebola virus disease: an emerging and re-emerging viral threat. J Autoimmun. 2020;106:102375. doi:10.1016/j.jaut.2019.102375
   PubMed Web of Science ®Google Scholar
• Dhawan M, Priyanka PM, Angural S, Choudhary OP, Choudhary OP. Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks. Int J Surg. 2022;97:106204. doi:10.1016/j.ijsu.2021.106204
   PubMed Web of Science ®Google Scholar
• Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. doi:10.1016/j.autrev.2020.102554
   PubMed Web of Science ®Google Scholar
• Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14(2):152–157. doi:10.2450/2015.0131-15
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi:10.1093/infdis/jiu396
   PubMed Web of Science ®Google Scholar
• Planitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis. 2007;196(3):435–440. doi:10.1086/519392
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–456. doi:10.1093/cid/ciq106
   PubMed Web of Science ®Google Scholar
• Garraud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23(1):39–44. doi:10.1016/j.tracli.2015.12.003
   PubMed Web of Science ®Google Scholar
• Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–89. doi:10.1038/nrneurol.2014.253
   PubMed Web of Science ®Google Scholar
• Wenjing L, Yuanzheng F, Li JY, Tang LV, Yu H. Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis. Aging. 2020;13(1):1498–1509. doi:10.18632/aging.202195
   PubMedGoogle Scholar
• Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325(12):1185–1195. doi:10.1001/jama.2021.2747
   PubMed Web of Science ®Google Scholar
• Zeng H, Wang D, Nie J, et al. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther. 2020;5(1):219. doi:10.1038/s41392-020-00329-x
   PubMed Web of Science ®Google Scholar
• Suryananda TD, Yudhawati R. Association of serum KL-6 levels on COVID-19 severity: a cross-sectional study design with purposive sampling. Ann Med Surg (Lond). 2021;69:102673. doi:10.1016/j.amsu.2021.102673
   PubMed Web of Science ®Google Scholar
• Saputra GNR, Yudhawati R, Fitriah M. Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: a cross-sectional study. Ann Med Surg (Lond). 2022;74:103303. doi:10.1016/j.amsu.2022.103303
   PubMed Web of Science ®Google Scholar
• Yudhawati R, Sakina S, Fitriah M. Interleukin-1β and interleukin-10 profiles and ratio in serum of COVID-19 patients and correlation with COVID-19 severity: a time series study. Int J Gen Med. 2022;15:8043–8054. doi:10.2147/ijgm.S381404
   PubMed Web of Science ®Google Scholar
• Asmarawati TP, Suryantoro SD, Rosyid AN, et al. Predictive value of sequential organ failure assessment, quick sequential organ failure assessment, acute physiology and chronic health evaluation II, and new early warning signs scores estimate mortality of COVID-19 patients requiring intensive care unit. Indian J Crit Care Med. 2022;26(4):464–471. doi:10.5005/jp-journals-10071-24170
   PubMed Web of Science ®Google Scholar
• Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 2021;118:102598. doi:10.1016/j.jaut.2021.102598
   PubMed Web of Science ®Google Scholar
• Harvala H, Robb ML, Watkins N, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2021;31(3):167–175. doi:10.1111/tme.12746
   PubMed Web of Science ®Google Scholar
• Pang NY, Pang AS, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res. 2021;8(1):47. doi:10.1186/s40779-021-00342-3
   PubMed Web of Science ®Google Scholar
• Yang Y, Du L. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies. Signal Transduct Target Ther. 2021;6(1):95. doi:10.1038/s41392-021-00523-5
   PubMed Web of Science ®Google Scholar
• Mortaz E, Tabarsi P, Varahram M, Folkerts G, Adcock IM. The immune response and immunopathology of COVID-19. Front Immunol. 2020;11:2037. doi:10.3389/fimmu.2020.02037
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–9496. doi:10.1073/pnas.2004168117
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.4783
   PubMed Web of Science ®Google Scholar
• Lu Q, Zhu Z, Tan C, et al. Changes of serum IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. 2021;75(9):e14462. doi:10.1111/ijcp.14462
   PubMed Web of Science ®Google Scholar
• Wang Y, Huo P, Dai R, et al. Convalescent plasma may be a possible treatment for COVID-19: a systematic review. Int Immunopharmacol. 2021;91:107262. doi:10.1016/j.intimp.2020.107262
   PubMed Web of Science ®Google Scholar
• Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020;136(6):755–759. doi:10.1182/blood.2020007079
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049–2059. doi:10.1016/s0140-6736(21)00897-7
   PubMed Web of Science ®Google Scholar
• Salazar E, Christensen PA, Graviss EA, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290–2303. doi:10.1016/j.ajpath.2020.08.001
   PubMed Web of Science ®Google Scholar
• Sewell HF, Glenn G, Bram K, Klein C. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19. BMJ. 2020;370:m2722. doi:10.1136/bmj.m2722
   PubMedGoogle Scholar
• Ostrovskaya E, Kostin A, Bulanov AY. Efficiency and safety of convalescent plasma therapy in patients with COVID-19: a systematic review. Ann Crit Care. 2022;2022(2):108–120. doi:10.21320/1818-474X-2022-2-108-120
   Google Scholar
• Liu Y, Tan W, Chen H, et al. Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19. BMC Infect Dis. 2021;21(1):79. doi:10.1186/s12879-021-05792-7
   PubMed Web of Science ®Google Scholar